Type 2 diabetes is well recognized as an independent risk factor for cardiovascular disease (CVD). In turn, CVD is the leading cause of morbidity and mortality in patients with type 2 diabetes. The impact of glycemic control in reducing microvascular complications is now well accepted. Although improving glycemic control is also beneficial for the prevention of macrovascular diseases, adequate treatment of hypertension and hyperlipidemia is also essential. In fact, studies have repeatedly demonstrated the safety and efficacy of antihypertensive and antihyperlipidemic therapies for the prevention of CVD in patients with type 2 diabetes. This article reviews the impact of commonly used antidiabetic, antihyperlipidemic, antihypertensive and antiplatelet agents on reducing CVD risk in patients with type 2 diabetes.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Publishing in Clinical Medicine Reviews in Vascular Health was a pleasant experience. The process was fast and fair. The staff were very professional and we were well informed of the progress of the manuscript.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)